Fibrates are a class of medications used to treat hypercholesterolemia and dyslipidemia that target nuclear peroxisome proliferator-activated receptors (PPARs). Studies have shown the PPARa agonist fenofibrate decreases voluntary EtOH consumption however its impact on the reinforcing and motivational effects of EtOH is unknown. We evaluated the ability of fenofibrate (25, 50 and 100 mg/kg), to alter EtOH (10%, w/v) and sucrose (2%, w/v) operant self-administration in rats under a FR2 schedule of reinforcement over four days and under a progressive ratio (PR) schedule on day five of treatment. Results showed fenofibrate dose-dependently decreased EtOH self-administration under both schedules of reinforcement with the greatest effects seen after four to five days of treatment. Fenofibrate decreased responding for sucrose only under the PR schedule of reinforcement and this effect was not dosedependent. These findings provide further evidence for fenofibrate as a potential treatment for alcohol use disorder in humans.
Introduction
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that regulate gene expression via their actions as ligand-activated transcription factors (Michalik et al., 2006) . Activated PPARs regulate gene expression after heterodimerizing with the retinoid X receptor and bind to PPAR response elements located in target gene promoters. Three PPAR isoforms (a, b, and у) have been identified to date (Berger and Moller, 2002) .
PPARa in particular, is involved in energy homeostasis by influencing gluconeogenesis, peripheral triglyceride levels and the breakdown of fatty acids and cholesterol. Accordingly, PPARa receptors are located in organs involved in fatty acid catabolism (e.g. brown adipose tissue, liver, intestines). PPARa receptors are also present throughout the central nervous system (Heneka and Landreth, 2007; Moreno et al., 2004) . Commonly known endogenous ligands for PPARa include oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and anandamide (Sun et al., 2006) . Distribution of PPARa in brain and the observation that these receptors may play a role in modulating dopamine (DA) neurotransmission and thus, drug reinforcement, has led to increased attention on ligands targeting PPARs as potential treatments for substance use disorders (Le Foll et al., 2013; Melis et al., 2013a) . Indeed, PPARa's are found within limbic structures and expressed on tyrosine-hydroxylase positive neurons (tyrosine-hydroxylase positive) (Moreno et al., 2004; Plaza-Zabala et al., 2010) . Administration of the endogenous PPARa ligand, OEA, decreases food consumption and reinforcement that is mediated by central DA neurotransmission (Fu et al., 2003; Plaza-Zabala et al., 2010; Rodriguez de Fonseca et al., 2001; Tellez et al., 2013) . Further, increasing endogenous levels of ligands for PPARa or administration of agonists decrease activation of the mesolimbic DA system and attenuate the behavioral effects of nicotine and morphine (Fernandez-Espejo et al., 2009; Luchicchi et al., 2010; Mascia et al., 2011; Melis et al., 2010 Melis et al., , 2008 Melis et al., , 2013b Panlilio et al., 2012) . Accordingly, evidence indicates that PPARa agonists reduce voluntary ethanol (EtOH) self-administration in rodents; however, results have not been consistent.
The fibrates are a drug class of synthetic ligands for PPARs indicated for the treatment of hypercholesterolemia and dyslipidemia. Recent studies have shown the PPARa agonist fenofibrate (a pro-drug for fibrinic acid) decreases voluntary EtOH consumption in mice (Blednov et al., 2016a; Ferguson et al., 2014) and rats (Karahanian et al., 2014) . Similarly, gemfibrozil, a PPARa partial agonist, also decreases voluntary EtOH intake in rats (Barson et al., 2009 ). Yet an earlier report showed that the prototypical PPARa agonist, clofibrate, dramatically increased voluntary EtOH drinking (Schlicht, 1987) whereas another study showed the opposite effect (Lamboeuf and De Saint Blanquat, 1980) . The aforementioned studies used 2-bottle choice and voluntary drinking tests. There have been no studies assessing the effects of fenofibrate on operant oral self-administration, a behavioral paradigm that can better assess EtOH's reinforcing and motivational properties. To achieve this, we tested various doses of fenofibrate on oral operant EtOH self-administration using a fixed ratio (FR) schedule of reinforcement where the response requisite is kept fixed throughout testing. We also used a progressive ratio (PR) schedule of reinforcement where the response requisite is progressively increased over the test session. Potential effects of fenofibrate were similarly assessed under both schedules of reinforcement in rats self-administering a sucrose solution.
Materials and methods

Animals and housing
A total of 14 Wistar rats (Charles River, Wilmington, MA) were housed two to a cage in standard polypropylenIe, shoe-box cages with wire tops located within a temperature-and humiditycontrolled vivarium that was maintained on a 12:12 light/dark cycle (lights on at 6 a.m.). Rats weighed about 350 g at the start of the experiment and were at least 100 days old. Food and water were available ad libitum except for 1e2 days in which.
Water access was restricted for 23-h in order to induce lever pressing for fluids in the operant chamber at the beginning of the training period (see below). Fig. 1 depicts the experimental procedure followed in the present study. One group of rats (EtOH group; N ¼ 7) was housed individually in EtOH vapor chambers (La Jolla Alcohol Research, La Jolla, CA) for 6-weeks prior to operant training using a chronic intermittent exposure (CIE) inhalation schedule known to induce EtOH-dependence (i.e., alcohol vapors were on for 14-h and off for 10-h, 5 days per week) (O'Dell et al., 2004) . This CIE inhalation schedule continued throughout the duration of the study. Another group of rats served as sucrose responding controls (SUCROSE group; N ¼ 7). All procedures were approved by the Institutional Animal Care and Use Committee in accordance with the National Institutes of Health Guidelines.
Drugs
The two fluids available for delivery in the operant chambers, sucrose (Calbiochem, La Jolla, CA) and alcohol (ethyl alcohol, 190 Proof, USP grade, Koptec, King of Prussia, PA), were made at concentrations of 2% (sucrose; w/v) and 10% (alcohol; w/v) using tap water. Fenofibrate was purchased from Sigma (St. Louis, MO) and was dissolved in H 2 O with 50 mL of Tween-80 added. The three doses of fenofibrate (25, 50, and 100 mg/kg) were prepared in a volume of 1 ml and administered intra-gastrically (PO) on a mg/kg basis 1-hr prior to the onset of test sessions. Each dose was given for five consecutive days in a non-systematic order across rats with at least 1 week intervening between dose presentations.
Behavioral apparatus
Seven, standard operant chambers (Coulbourn Instruments, Allentown, PA) enclosed in sound-attenuating cubicles (Coulbourn Instruments) were used in the present study. Each chamber was equipped with two levers located on either side of an access area into which a dipper (0.1 mL capacity) could protrude. Prior to activation, the dipper was maintained in a small reservoir of fluid (sucrose or EtOH). Infrared sensors located in the dipper access area provided the means to tabulate numbers of head entries. A house light, a dipper access area light, and two sets of three, colored cue lights, one above each lever, were located within the operant chamber. Stimulus parameters and data tabulation were programmed using Graphic State Notation (version 4.0).
Operant self-administration training
Rats were put on fluid restriction prior to the first day of training. Training sessions (1-hr in length) began with the illumination of the house light. Initially, a head entry into the dipper access area triggered the protrusion of the dipper for 15-s with a 5-s inter-trial interval. The dipper access light would be illuminated for the entire length of the dipper presentation time. Dipper presentation times were gradually reduced over a week of training, based on each animal's performance, until they were 3-s in duration. Levers were retracted during this phase of training. During the next phase of training, the levers protruded at the start of the session, signaled by the illumination of the house light, and two "primes" (dipper presentations) were given. Then, when the rat pressed the active lever, the house light would turn off, the dipper would protrude, and the access area light and the triple cue light above this lever became illuminated. Presses on the inactive lever had no programmed consequences. Once a rat emitted 25 active lever presses with 20% variability or less in response levels over 2-days, the ratio requirement was raised to fixed-ratio 2 (FR2), the schedule used for the rest of the training. Stable response levels under the FR2 schedule ( 20% variability over 2-days) were required for the animal to move into the testing phase.
Operant self-administration testing
Test sessions were conducted 5-days a week, 7e8 h s after CIE to EtOH vapor. On Monday-Thursday, a 1-hr session under the FR2 schedule was conducted. The Friday test session was conducted under a progressive ratio (PR) schedule (e.g. 1, 1, 2, 2, 3, 3, 4, 4, 5, 5, 7, 7, 9, 9, 11, 11, 13, 13, 15, 15, 18, 18, 21, 21, 24, 24, etc.) and was 3-h in duration as described previously (Kosten, 2011; Walker and Koob, 2007) . Each dose of fenofibrate and its vehicle were administered 1 h prior to the test sessions over these 5-days of testing. At least 1-wk intervened between dose test weeks in order to ensure that response levels had returned to pre-drug, baseline levels.
Statistical analysis
Data from the FR and PR tests for both groups were analyzed separately and included numbers of active and inactive lever presses and reinforcers earned (dipper presentations). The four days of FR2 tests were analyzed using a 4 Â 4 ANOVA representing factors of fenofibrate dose (0, 25, 50, 100 mg/kg) with repeated measures on Day. Significant main effects were followed by posthoc pairwise multiple comparisons using Bonferroni t-test. Data from the PR test sessions for active and inactive lever presses and reinforcers earned were analyzed using ANOVA with fenofibrate dose (0, 25, 50, 100 mg/kg) as the factor. Significant main effects were followed by post-hoc pairwise multiple comparisons using Student-Newman-Keuls Method. P-value considered significant was set at <0.05.
Results
Alcohol and sucrose self-administration
FR2 tests
The numbers of active and inactive lever presses emitted over the four days of tests conducted under the FR2 schedule of reinforcement are shown in Table 1 for both EtOH and sucrose groups. Analysis of active lever presses emitted by the EtOH group revealed a significant main effect for fenofibrate Dose (F (3,111) ¼ 42.696; P < 0.001) and Day (F (3,111) ¼ 15.990; P < 0.001) and a Dose Â Day interaction (F (9,111) ¼ 3.403; P ¼ 0.002). Post-hoc analysis of active lever presses following the main effect for Dose indicated a significant difference between all fenofibrate doses (P's¼<0.05-<0.001). Post-hoc analysis following the main effect for Day showed the numbers of active lever presses significantly differed between all days (P's < 0.05) except Day 1 vs. Day 2 and Day 2 vs Day 3 (P's > 0.05). Post-hoc analysis following the significant Dose Â Day interaction showed comparisons for factor Day within Dose revealed significantly lower active lever.
Presses on Day 4 compared to Days 1 and 2 (P's < 0.01) following 25 mg/kg fenofibrate. Further, active lever presses were significantly lower (P's < 0.05) on Days 3 and 4 compared to Day 1 following both 50 mg/kg and 100 mg/kg fenofibrate. Post-hoc comparisons for factor of Dose within Day for the EtOH group revealed lower active lever presses following 100 mg/kg compared to the 25 mg/kg fenofibrate dose (P < 0.01) across all days. Moreover, active lever presses were significantly lower following all fenofibrate doses (25, 50, 100 mg/kg) compared to 0 mg/kg on days 3 and 4 (P's < 0.05). Analysis of inactive lever presses revealed a significant main effect for fenofibrate dose (F (3,111) ¼ 4.430; P ¼ 0.017) but not Day (F (3,111) ¼ 0.982; P ¼ 0.423) and no interaction (F (9,111) ¼ 1.018; P ¼ 0.438). Post-hoc comparisons following the main effect for fenofibrate dose revealed overall decreases in inactive lever presses following 50 and 100 mg/kg fenofibrate compared to 0 mg/kg (P's < 0.05).
Analysis of active lever presses for the FR tests in rats selfadministering sucrose revealed no main effects for fenofibrate dose (F (3,111) ¼ 0.214; P ¼ 0.886) nor Day (F (3,111) ¼ 2.947; P ¼ 0.061). Analysis of inactive lever presses revealed a significant main effect for fenofibrate dose (F (3,111) ¼ 12.510; P < 0.001) but not for Day (F (3,111) ¼ 1.66; P ¼ 0.210) and no interaction (F (9,111) ¼ 1.259; P ¼ 0.280). Post-hoc analysis following the main effect for fenofibrate dose revealed significant decreases in inactive lever presses 25 mg (P < 0.05) and 100 mg/kg (P < 0.01) compared to 0 mg/kg and 100 mg/kg compared to 50 mg/kg (P < 0.01).
The number of reinforcers earned under the FR tests across days for the EtOH and sucrose groups is presented in Fig. 2A and B respectively. For the EtOH group, analysis revealed a significant main effect for fenofibrate dose (F (3,111) ¼ 47.969; P < 0.001), Day (F (3,111) ¼ 15.384; P < 0.001) and a fenofibrate dose Â Day interaction (F (9,111) ¼ 3.216; P ¼ 0.003). Post-hoc analysis of reinforcers earned following the main effect for Dose indicated a significant difference between all fenofibrate doses (P's¼<0.02-<0.001). Posthoc analysis following the main effect for Day showed the numbers of reinforcers earned significantly differed between all days (P's < 0.05) except Day 1 vs. Day 2 and Day 2 vs Day 3 (P's > 0.05). Post-hoc analysis following the significant Dose Â Day interaction showed comparisons for factor Day within Dose revealed significantly lower numbers of reinforcers earned on Day 4 compared to Day 1 (P < 0.001) and Day 2 (P ¼ 0.005) following 25 mg/kg Fig. 1 . Experimental procedure timeline of rats orally self-administering EtOH (ethyl alcohol). Rats were exposed to chronic intermittent exposure (CIE) to EtOH vapor prior to being trained to lever-press for EtOH. CIE inhalation continued throughout the duration of the study (5 days on, 2 days off). Following acquisition, rats were administered a test dose of fenofibrate (0, 25, 50, 100 mg/kg, PO) for 5 consequitive days. Testing occurred under both fixed (FR2) and progressive ratio (PR) schedules of reinforcement. One week of maintenance of EtOH separated each fenofibrate test dose. Another group of rats were trained to self-administer a sucrose solution that were not exposed to EtOH vapor. Significant main effect for^fenofibrate dose, #day and ¥ dose Â day interaction. Bolded measures: **Significant difference from 0 mg/kg, P < 0.01. Bold measures with no symbols indicates significant difference from Day 1 (P < 0.05). y Significantly different from 0 mg/kg, P < 0.05.
fenofibrate. Further, reinforcers earned were significantly lower (P's < 0.05) on Days 3 and 4 compared to Day 1 following both 50 mg/kg and 100 mg/kg fenofibrate. Post-hoc comparisons for factor of Dose within Day revealed lower numbers of reinforcers earned following 100 mg/kg compared to the 25 mg/kg fenofibrate dose (P < 0.01) across all days. As shown in Fig. 2A , reinforcers earned were significantly lower following all fenofibrate doses (25, 50, 100 mg/kg) compared to 0 mg/kg on days 3 and 4 (P's < 0.05). Reinforcers earned across days for the sucrose group are presented in Fig. 2B . Analysis revealed no main effect for fenofibrate dose (F (3,111) ¼ 0.132; P ¼ 0.940) nor Day (F (3,111) ¼ 2.872; P ¼ 0.065).
PR tests
Data generated from the PR tests are presented in Table 2 . Analysis of active lever presses for the EtOH group revealed a significant main effect for fenofibrate dose (F (3,27) ¼ 46.895; P < 0.001). Post-hoc comparisons following the significant main effect for.
Fenofibrate dose indicated significant differences between all doses (P's < 0.01). There was no main effect for fenofibrate dose (F (3,27) ¼ 1.079; P ¼ 0.377) on inactive lever presses.
Analysis of active lever presses in rats self-administering sucrose under the PR schedule of reinforcement revealed a main effect for fenofibrate dose (F (3,27) ¼ 9.880; P < 0.001). Post-hoc analysis following the main effect for fenofibrate dose revealed significant decreases in active lever presses following 25 mg, 50 mg and 100 mg/kg fenofibrate compared to 0 mg (P's < 0.01). A significant main effect for fenofibrate dose was also found following analysis of inactive lever presses elicited by the sucrose group (F (3,27) ¼ 8.168; P < 0.001). Post-hoc analysis following the main effect for fenofibrate dose revealed significant decreases in inactive lever presses following 25 mg, 50 mg and 100 mg/kg fenofibrate compared to 0 mg (P's < 0.01).
Reinforcers earned under the PR tests for both EtOH and sucrose groups are presented in Fig. 3A and B respectively. Analysis of reinforcers earned for the EtOH group revealed a significant main effect for fenofibrate dose (F (3,27) ¼ 36.361; P < 0.001). Post-hoc pairwise multiple comparisons revealed significant differences between all fenofibrate doses (P's < 0.01) in a dose-response manner (Fig. 3A) . Analysis of reinforcers earned for the sucrose group revealed a significant main effect for fenofibrate dose (F (3,27) ¼ 12.472; P < 0.001). Post-hoc pairwise multiple comparisons revealed significant differences between 0 mg/kg and 25, 50 and 100 mg/kg fenofibrate doses (P's < 0.01).
Discussion
The results of the present study show that administration of fenofibrate, a preferential PPARa agonist, led to a dose-dependent decrease in the reinforcing and motivational effects of EtOH with the greatest impact seen after about three to four days of treatment. Fenofibrate did not alter responding for sucrose under a FR2 schedule of reinforcement however it did decrease responding under a PR schedule of reinforcement. Unlike the effects of fenofibrate seen on EtOH self-administration, altered responding for sucrose was not dose-related and appeared non-selective. Nonetheless, the present study is the first to show fenofibrate decreases operant oral EtOH self-administration in rats under two schedules of reinforcement. These data are consistent with a majority of previous studies assessing fenofibrate on oral voluntary EtOH selfadministration in rodent.
Results from the present study are largely congruent with previous studies assessing the impact of PPARa agonists on the behavioral effects of EtOH. For example, Ferguson et al. showed pretreatment with fenofibrate (150 mg/kg/8 days, PO) decreased Fig. 2 . Effects of various doses of fenofibrate on reinforcers earned (mean ± SEM) in rats self-administering ethanol (A.,EtOH, 10%, N ¼ 7) or sucrose (B., 2%, N ¼ 7) under a FR2 schedule of reinforcement. Rats were administered various doses of fenofibrate for four days. Fenofibrate decreased reinforcers earned in rats self-administering EtOH but not sucrose. Compared to control (0 mg/kg), decreases in reinforcers earned following fenofibrate were more prominent for all doses on Days 3 and 4. **P < 0.01. EtOH group: all fenofibrate doses differed from each other, **p < 0.01, *p < 0.05. Sucrose group: *significant difference from 0 mg/kg, p < 0.01, **significant difference from 0 mg/kg, p < 0.01.
EtOH (15%) consumption in mice using a continuous access twobottle choice drinking procedure (Ferguson et al., 2014) . A more recent study showed similar results following fenofibrate (100 and 150 mg/kg, PO) administration in mice using continuous and intermittent 2-bottle choice EtOH (15%) drinking tests (Blednov et al., 2016a) . In that same study, fenofibrate administration in mice lacking PPARa did not alter EtOH consumption but did in wildtype mice thus showing specificity. Similarly, at a dose of fenofibrate that significantly reduced EtOH self-administration in the present study, Karahanian et al. showed fenofibrate (50 mg/kg/14 days, PO) decreased voluntary EtOH (10%) consumption in highdrinker UChB rats (Karahanian et al., 2014) . Further, the PPARa partial agonist gemfibrozil (50 mg/kg, PO), decreased EtOH intake in rats voluntarily consuming a 7% alcohol solution (Barson et al., 2009) . In contrast to these and the present study, Schlicht showed that daily administration of the prototypical PPARa agonist clofibrate (300 mg/kg/day) in food fed to Spontaneously Hypertensive Rats dramatically increased voluntary consumption of a high concentration of EtOH (30%) compared to controls (Schlicht, 1987) . These contradictory findings may be attributed to a number of methodological differences including dose, administration route of the PPARa agonist, rat strain, and uncommonly high concentration of EtOH used. Nevertheless, results of the present study are in line and extend previous studies assessing the impact the PPARa agonist fenofibrate on EtOH-reinforced behavior in rodents. Our data indicate that the effect of fenofibrate on sucrose reinforcement appears to be non-specific. In contrast to dose-related effects seen in rats self-administering EtOH under a FR2 schedule of reinforcement, fenofibrate did not decrease active lever presses (Table 1) nor reinforcers earned (Fig. 2B ) in rats self-administering sucrose. This finding is consistent with a recent study in mice (2-bottle choice test 24-hour access) showing fenofibrate did not alter saccharin intake (Blednov et al., 2016b) . Fenofibrate did however decrease active as well as inactive lever presses and reinforcers earned under a PR schedule of reinforcement for sucrose (Table 2 and Fig. 3B ). Yet this effect was not dose-related as was the case with fenofibrate's effects on both FR and PR schedules of reinforcement for EtOH. That the effects of fenofibrate on number of active lever presses emitted and reinforcers earned under both FR and PR schedules in the EtOH group implies that decreases in EtOH-reinforced behavior are specific to fenofibrate. This effect was also dose-related. Because fenofibrate did decrease sucrose selfadministration under the PR schedule may reflect differences in the sensitivity between the schedules of reinforcement utilized to detect drug effects on reinforced behavior. Given the role of PPARa in lipid metabolism, satiety and food consumption however, it is not surprising that fenofibrate significantly decreased sucrose reinforcement (Michalik et al., 2006) . Indeed, endogenous PPARa ligands, such as OEA, and synthetic PPARa agonists (e.g. WY14643, GW7647) decrease food consumption and body weight in wildtype and obese mice but not in PPARa knock-out mice (Fu et al., 2003; Tellez et al., 2013) . In accord with our results, numerous studies using a variety of rat and mouse obesity models have consistently shown fenofibrate decreases food consumption (Jeong and Yoon, 2009; Lee et al., 2002; Park et al., 2012) . The present study extends this effect of fenofibrate to the motivational aspects of sucrose self-administration.
The mechanism(s) responsible for the ability of fenofibrate to decrease EtOH reinforcement are presently unknown, however, both central and peripheral targets have been proposed. EtOH is metabolized into acetaldehyde and then to acetate by the liver through three primary enzymatic reactions involving alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), and catalase. Drugs that increase activity of these enzymes augment EtOH metabolism into acetate. For example, blockade of ALDH increases systemic levels of acetaldehyde that may be aversive and presumably, contribute to the marginally successful use of the ALDH inhibitor disulfiram, for the treatment of alcohol use disorder in humans. It appears however that disulfiram's therapeutic effects are likely due to it acting centrally (Gaval-Cruz and Weinshenker, 2009). Nevertheless, evidence indicates PPAR agonists can alter EtOH elimination. For example, consistent with facilitation of ethanol elimination, bezafibrate and clofibrate, increase ALDH and peroxisomal beta-oxidation activity that results in decreased blood EtOH and acetaldehyde levels and increased acetate concentrations following EtOH (Hawkins et al., 1974; Kramar and Kremser, 1984; Lamboeuf and De Saint Blanquat, 1980; Tsukamoto et al., 1996) . Another report shows that fenofibrate increased blood acetaldehyde levels and liver catalase activity following voluntary alcohol drinking (10%), but does not alter liver ALDH levels (Karahanian et al., 2014) . Although these data suggest that fenofibrate facilitates EtOH clearance, blood EtOH levels were not assessed (Karahanian et al., 2014) . A recent study using mice evaluated the effects of fenofibrate (150 mg/kg) on EtOH clearance following an IP injection of EtOH (4.0 g/kg) measured over 5 time points (30, 60, 120, 180 and 240 min) (Blednov et al., 2016a) . Results indicate that fenofibrate facilitated EtOH clearance. It would stand to reason that if fenofibrate facilitated the metabolism of EtOH, rats would have Fig. 3 . Effects of various doses of fenofibrate on reinforcers earned (mean ± SEM) in rats self-administering ethanol (A.,EtOH, 10%, N ¼ 7) or sucrose (B., 2%, N ¼ 7) under a PR schedule of reinforcement. Rats were administered various doses of fenofibrate for five days. Fenofibrate decreased reinforcers earned in both groups. Fenofibrate dose-dependently decreased reinforcers earned in rats self-administering EtOH, but not sucrose. **P < 0.01. compensated by increasing responding for EtOH. Our data would appear to be consistent if EtOH elimination was delayed since fenofibrate decreased EtOH self-administration in the present study. Moreover, the PPARa/g/b mixed agonist bezafibrate, which has been shown to decrease blood EtOH levels, does not reduce voluntary EtOH self-administration (Ferguson et al., 2014; Tsukamoto et al., 1996) . Nevertheless, it is unlikely that the impact of fenofibrate on EtOH self-administration found in the present study was due strictly to altered EtOH elimination, although studies are needed to directly assess this possibility.
It has been proposed that fenofibrate's ability to decrease voluntary EtOH consumption may be due to its ability to act peripherally by enhancing liver catalase activity in turn, increasing systemic acetaldehyde levels that are presumably aversive (Karahanian et al., 2014 (Karahanian et al., , 2015 . Evidence suggests however, that acetaldehyde is reinforcing on its own. For example, studies have shown it is self-administered orally, intravenously, directly into the ventricles and into the VTA (Muggironi et al., 2013) . Further, drugs that prevent the formation of acetaldehyde and acetaldehyde chelators block EtOH's rewarding effects (Font et al., 2006a, b; Peana et al., 2008) . In addition to EtOH, we found that fenofibrate also decreased sucrose reinforcement, an effect not likely attributed to increases in systemic acetaldehyde levels. A more likely mechanism underlying fenofibrate's effects on EtOH self-administration is action through the PPARa (Blednov et al., 2016a) influencing DA neurotransmission within the mesolimbic system (Melis et al., 2013a) . It is more plausible however that fenofibrate, and PPARa agonists in general, block EtOH's behavioral effects through multiple mechanisms (Ferguson et al., 2014) .
Conclusions
The present study demonstrated that the preferential PPARa agonist fenofibrate decreased operant oral EtOH selfadministration in a dose-dependent manner. Fenofibrate also decreased sucrose reinforcement but this was not dependent upon dose and observed only under a PR schedule of reinforcement. Our results are consistent with other studies assessing the effects of fenofibrate on voluntary alcohol consumption and extend its effects to contingency-dependent EtOH reinforcement. Fenofibrate is presently approved for the treatment of hypercholesterolemia and dyslipidemia. Results from our study and others support the notion that fenofibrate should also be assessed for the treatment of alcohol use disorder in humans.
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